[Evaluation of prostate cancer using FDG-PET]

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Prostate cancer diagnosis and staging rely on various imaging modalities.
• 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is an imaging technique that measures metabolic activity.

Purpose of the Study:

• To evaluate the clinical usefulness of FDG-PET in patients with prostate cancer.
• To determine if FDG-PET can serve as a reliable tool for tumor detection and prognostic assessment.

Main Methods:

• 54 patients with prostate cancer underwent FDG-PET imaging.
• FDG accumulation was assessed in primary tumors and metastases.
• Standardized uptake values (SUV) were correlated with histological grade, clinical stage, and serum PSA levels.

Main Results:

• FDG-PET showed positive uptake in 70% of prostates, 38% of lymph node metastases, and 63% of bone metastases.
• FDG-PET was not superior to conventional methods for tumor detection.
• SUV significantly correlated with histological grade, clinical stage, and PSA.
• Decreased SUV indicated response to endocrine treatment, while high pre-treatment SUV predicted disease progression.

Conclusions:

• FDG-PET has limited sensitivity for detecting prostate cancer and its metastases.
• FDG-PET-derived SUV provides valuable prognostic information, reflecting tumor malignancy and predicting treatment outcomes in prostate cancer patients.